Collegium制药 COLL 深 沪
已收盘 12-12 16:00:00 美东时间
48.63
+0.270
+0.56%
华盛通- 最 高48.965
- 今 开48.525
- 成交量 36.94万股
- 最 低 47.855
- 昨 收 48.36
- 总市值 15.32亿
- 52周最高 49.155
- 市盈率 静 26.19
- 换手率 1.17%
- 52周最低 23.23
- 委 比 60.24%
- 总股本 3150.21万
- 历史最高 49.155
- 量 比 0.70
- 振 幅 2.30%
- 历史最低 7.37
- 每 手 1
- 风险率 5.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Barclays Initiates Coverage On Collegium Pharmaceutical with Overweight Rating, Announces Price Target of $58
Barclays analyst Glen Santangelo initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight rating and announces Price Target of $58.
12-09 23:36
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Collegium Pharmaceutical shares are trading higher after the company reported better-than-expected Q3 financial results and raised FY2025 revenue outlook.
Collegium Pharmaceutical shares are trading higher after the company reported b...
11-06 20:40
Collegium Pharmaceutical Raises FY2025 Sales Guidance from $745.000M-$760.000M to $775.000M-$785.000M vs $751.631M Est
Financial Guidance for 2025The Company updates its full-year 2025 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA:PriorUpdated Product Revenues, Net$745 - $760 million$775 - $785
11-06 20:37
Collegium Pharmaceutical Q3 Adj. EPS $2.25 Beats $2.04 Estimate, Sales $209.361M Beat $189.118M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $2.04 by 10.08 percent. This is a 39.75 percent increase over earnings of $1.61 per share
11-06 20:36
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
Paris Hilton collaborates with Collegium Pharmaceutical to share her ADHD journey and encourage treatment. ADHD affects millions in the U.S., with many experiencing symptoms into adulthood. Hilton, diagnosed as a young adult, now advocates for awareness and appropriate treatment options. She uses JORNAY PM, a stimulant medication, and aims to reduce stigma around ADHD. The collaboration highlights the importance of discussing ADHD with healthcare...
10-29 12:00
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
